×
For best experience we recommend to activate Javascript in your browser.
Recombinant IL6 (Ziltivekimab Biosimilar) antibody
The Human Monoclonal anti-IL6 (Ziltivekimab Biosimilar) antibody has been validated for ELISA, BLI, FACS, Func and SPR. It is suitable to detect IL6 (Ziltivekimab Biosimilar) in samples from Human.
Catalog No. ABIN7676036
$294.23
$346.15
save $51.92 (-15 %)
Plus shipping costs $50.00
1 mg ABIN7581526
100 μg ABIN7676036
1 mg ABIN7581526
100 μg ABIN7676036
Delivery in 10 to 11 Business Days
Quick Overview for Recombinant IL6 (Ziltivekimab Biosimilar) antibody (ABIN7676036)
Target
IL6 (Ziltivekimab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for IL6 (Ziltivekimab Biosimilar) antibodies
Human
Clonality
All clonalities for IL6 (Ziltivekimab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for IL6 (Ziltivekimab Biosimilar) antibodies
This IL6 (Ziltivekimab Biosimilar) antibody is un-conjugated
Application
ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-IL6 (Ziltivekimab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-IL-6 / IFNb2 Reference Antibody (ziltivekimab)
Characteristics
Anti-IL-6 / IFNb2 Reference Antibody (ziltivekimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for IL6 (Ziltivekimab Biosimilar)
(hide)
Target
IL6 (Ziltivekimab Biosimilar)
Alternative Name
IL-6 (Ziltivekimab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
P05231
Recently viewed
(hide)
Chat with us , powered by LiveChat